Rocklin, United States
CPC Scientific Inc. is a prominent player in the peptide-focused contract research, development, and manufacturing organization (CRDMO) industry, securing the third position worldwide in sales revenue in 2023 based on data from Frost & Sullivan. The company's offering extends to encompass contract research organization, contract development and manufacturing organization, and contract manufacturing organization services, covering the entire life cycle from early discovery to commercial production. With a global reach spanning over 50 countries, including key markets in the US, China, Japan, Europe, South Korea, and Australia, CPC Scientific Inc. is well-positioned to provide comprehensive peptide drug development, production, and CMC filing support services to meet regulatory requirements globally.
Notably, the company has diversified its project pipeline to include various complex peptide- and oligonucleotide-based new chemical entities, signaling a commitment to innovation. Its introduction of PeptiConjuXTM and PeptiNuclide LinkTechTM highlights its focus on peptide conjugation services, enabling the development and large-scale manufacturing of peptide-oligonucleotide conjugates, peptide drug conjugates, and radionuclide drug conjugates. As of December 31, 2023, the company had synthesized approximately 1,800 molecules through these two platforms, showcasing its dedication to expanding its product offerings and capabilities.
Established in 2001, CPC Scientific Inc. operates within the Analytics, Biotechnology, and Pharmaceutical industries, positioning itself at the intersection of cutting-edge scientific advancements and market potential. Its impressive track record and global presence make it an intriguing prospect for potential investors seeking opportunities in the biotechnology and pharmaceutical sectors.
